CUE vs INCY · rev $13.6M vs P/E 14, rev $5.14B
Cue Biopharma (CUE) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported CUE revenue for 2026-06-30 was $13.6M. Net income was -$158.2M. CUE currently screens at market cap $59.5M.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
CUE currently screens at market cap $59.5M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the CUE and INCY stock pages for the full models.
Not investment advice.